Sign Out
No dedicated clinical interaction studies have been performed.
Clinical experience has not given evidence for potential interaction of Epoetin beta (Recormon) with other medicinal products (for more information see also Pharmacology: Toxicology: Nonclinical Safety under Actions).
In animal experiments epoetin did not increase the myelotoxicity of cytostatic medicinal products like etoposide, cisplatin, cyclophosphamide, and fluorouracil.
Continue with Google